Latest news with #CHOPlus
Yahoo
6 days ago
- Business
- Yahoo
CHO Plus Selected for 2025 BioTools Innovator Accelerator Program
Biomanufacturing Technology Developer Joins Top-Tier Global Cohort Competing for $300,000 in Cash Awards SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Privately-held CHO Plus, Inc., a leading developer of biopharmaceutical manufacturing technology, announced its selection for the 2025 BioTools Innovator Accelerator, the first and only program focused exclusively on life science tools and diagnostics companies. Chosen from over 400 applicants, CHO Plus is among just 31 startups to earn a spot in this year's prestigious cohort. BioTools Innovator provides a four-month accelerator program offering tailored mentorship from senior industry leaders, investor exposure, and networking opportunities with peers and experts across the global life science community. At the end of the program, companies will compete for $300,000 in non-dilutive cash prizes. 'We are honored to be recognized among the most promising innovators in life science tools and diagnostics,' said Lawrence Forman, Founder and CEO of CHO Plus, Inc. 'This opportunity will help us accelerate the development and commercialization of our high-productivity cell lines for biologics production. We're excited to engage with industry mentors, and to connect with peers as part of the BioTools Innovator ecosystem.' CHO Plus was also selected with nine other companies to participate in the VANGUARD Accelerator, a joint initiative with Biomedical Advanced Research and Development Authority (BARDA) to support companies advancing medical countermeasures for public health emergencies. VANGUARD is a joint initiative between BioTools Innovator and BARDA, part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, to support startups in deploying innovative medical countermeasures that enhance the U.S.'s readiness for public health emergencies.* As part of the BioTools Innovator 2025 program CHO Plus will participate in a series of events, including the Innovator Summit (June 24–26 in Mountain View, CA), pitch opportunities, and a final Capstone Event where companies will compete for a share of $300,000 in non-dilutive funding. *This project has been supported in whole or in part with funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under agreement number 75A50124C00034. About CHO Plus, Plus, a privately held company, was founded in 2014 with the mission of increasing the productivity of cells used for manufacturing life-saving therapeutic agents for treating human disease. CHO Plus has patents granted and pending for several different technologies in over ten jurisdictions around the world. Current CHO Plus studies demonstrate that our engineered CHO cells produce up to 10-fold more therapeutic antibodies than un-engineered cells and our engineered HEK-293 cells produce up to 20-fold more AAV vectors, with up to 55% full capsids before purification. With a focus on innovation and collaboration, the company is committed to advancing production of therapeutic proteins and gene therapy vectors to address a wide range of clinical conditions. About BioTools InnovatorBioTools Innovator (BTI), based in Los Angeles, advances cutting-edge research and improves human health by accelerating the growth of life science tools and diagnostics startups. Powered by MedTech Innovator, the world's largest accelerator for medical technology companies, BTI supports early-stage and emerging growth companies through mentorship, visibility, and non-dilutive funding more at Media ContactLawrence Forman, CHO Plus, Inc. Founder and CEOLarry@ 845 380 6993
Yahoo
08-04-2025
- Business
- Yahoo
U.S. Patent Issued for a Family of Sleeping Beauty Soluble Protein Cell Transfection Agents
CHO Plus has in-licensed the family of optimized transposase variants which can insert genetic elements into cells in a more controlled fashion SOUTH SAN FRANCISCO, Calif., April 08, 2025--(BUSINESS WIRE)--CHO Plus, Inc. ( a leading developer of biopharmaceutical manufacturing technology, announces that U.S. Patent No. 12,270,055 was issued today by the United States Patent and Trademark Office. EMBLEM Technology Transfer GmbH has licensed the patented technology to CHO Plus for transfecting cells to produce therapeutic agents. The patent covers a family of variants of Sleeping Beauty transposase that were developed by Dr. Orsolya Barabas, Dr. Irma Querques, and Dr. Cecilia Zulianiat at EMBL (the European Molecular Biology Laboratory). The crystal structure of the original transposase protein was determined, and used to identify regions that can be mutated to increase solubility. Making the protein more soluble confers several advantages: By transfecting cells with the transposase in soluble protein form, rather than as a nucleic acid vector, the user can closely control the number of gene copy insertions per genome; the transposase protein is more stable and reproducible than the nucleic acid versions; after transfection, the activity is rapidly cleared. CHO Plus has developed patented cell engineering technology that increases the capacity of cells to produce therapeutic proteins, and viral vectors for gene therapy—all with improved quality attributes. Current studies demonstrate that CHO Plus-engineered CHO cells produce up to five times more therapeutic antibody than un-engineered cells; CHO Plus-engineered HEK-293 cells produce up to 20 times more AAV vector, with up to 55% full capsids before purification. Larry Forman, Founder and CEO of CHO Plus, said: "We licensed this technology from EMBLEM because we recognized the benefits of optimizing gene insertion. The soluble Sleeping Beauty transposase protein is particularly well suited for inserting genes into our highly productive engineered cells. We intend to make the improved soluble transposase protein available for use in both biologics manufacturing and basic research through a commercial vendor." About CHO Plus, Inc. CHO Plus, a privately held company located in South San Francisco, was founded with the mission of increasing the productivity of cells used for manufacturing life-saving therapeutic agents for treating a wide range of clinical conditions. For more information, visit View source version on Contacts Joseph Tarnowski, CTO and CBO+1 (732) Sign in to access your portfolio
Associated Press
08-04-2025
- Business
- Associated Press
U.S. Patent Issued for a Family of Sleeping Beauty Soluble Protein Cell Transfection Agents
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 8, 2025-- CHO Plus, Inc. ( a leading developer of biopharmaceutical manufacturing technology, announces that U.S. Patent No. 12,270,055 was issued today by the United States Patent and Trademark Office. EMBLEM Technology Transfer GmbH has licensed the patented technology to CHO Plus for transfecting cells to produce therapeutic agents. The patent covers a family of variants of Sleeping Beauty transposase that were developed by Dr. Orsolya Barabas, Dr. Irma Querques, and Dr. Cecilia Zulianiat at EMBL (the European Molecular Biology Laboratory). The crystal structure of the original transposase protein was determined, and used to identify regions that can be mutated to increase solubility. Making the protein more soluble confers several advantages: By transfecting cells with the transposase in soluble protein form, rather than as a nucleic acid vector, the user can closely control the number of gene copy insertions per genome; the transposase protein is more stable and reproducible than the nucleic acid versions; after transfection, the activity is rapidly cleared. CHO Plus has developed patented cell engineering technology that increases the capacity of cells to produce therapeutic proteins, and viral vectors for gene therapy—all with improved quality attributes. Current studies demonstrate that CHO Plus-engineered CHO cells produce up to five times more therapeutic antibody than un-engineered cells; CHO Plus-engineered HEK-293 cells produce up to 20 times more AAV vector, with up to 55% full capsids before purification. Larry Forman, Founder and CEO of CHO Plus, said: 'We licensed this technology from EMBLEM because we recognized the benefits of optimizing gene insertion. The soluble Sleeping Beauty transposase protein is particularly well suited for inserting genes into our highly productive engineered cells. We intend to make the improved soluble transposase protein available for use in both biologics manufacturing and basic research through a commercial vendor.' About CHO Plus, Inc. CHO Plus, a privately held company located in South San Francisco, was founded with the mission of increasing the productivity of cells used for manufacturing life-saving therapeutic agents for treating a wide range of clinical conditions. SOURCE: CHO Plus, Inc. Copyright Business Wire 2025. PUB: 04/08/2025 10:42 AM/DISC: 04/08/2025 10:43 AM
Yahoo
18-03-2025
- Business
- Yahoo
CHO Plus Obtains U.S. Patent for Improved Production of Viral Vectors for Gene Therapy
Cell Engineering Technology Will Address Unmet Therapeutic Needs by Reducing Cost and Increasing Availability of Gene Therapy SOUTH SAN FRANCISCO, Calif., March 18, 2025--(BUSINESS WIRE)--CHO Plus, Inc. ( a leading developer of biopharmaceutical manufacturing technology, announced that U.S. Patent No. 12,252,713 was issued by the United States Patent and Trademark Office. The patent covers a procedure for fusing and screening cells to obtain cell hybrids that can be used to produce viral vectors for gene therapy. This is the first patent covering the use of cell hybrids to produce viral vectors. Adoption of CHO Plus technology could lead to significantly lower manufacturing costs for AAV and lentivirus vectors, while relieving supply constraints and improving product quality. Larry Forman, CHO Plus Founder, CEO, and co-inventor of this technology commented: "We are thrilled to achieve this milestone. The technology was developed through the hard work and creativity of our scientific staff. Some common diseases would be amenable to gene therapy, but they remain untreated due to high viral vector production costs and the inability to produce sufficient quantities of the viral vectors. CHO Plus technology offers a possible solution." Joseph Tarnowski, CHO Plus Chief Technology and Business Officer, added: "This is one of our two central technologies. Our other patented technology uses cell hybrids to increase production of antibodies and other proteins used in therapy. We hope to partner both our viral vector technology and protein production technology with large pharmaceutical companies and CDMOs to assist us with commercial development." Current CHO Plus studies demonstrate that our engineered CHO cells produce up to 10-fold more therapeutic antibodies than un-engineered cells and our engineered HEK-293 cells produce up to 20-fold more AAV vectors, with up to 55% full capsids before purification. With a focus on innovation and collaboration, the company is committed to advancing production of therapeutic proteins and gene therapy vectors to address a wide range of clinical conditions. About CHO Plus, Inc. CHO Plus, a privately-held company, was founded with the mission of increasing the productivity of cells used for manufacturing life-saving therapeutic agents for treating human disease. CHO Plus has patents granted and pending for several different technologies in over ten jurisdictions around the world. For more information, visit View source version on Contacts Joseph Tarnowski, CTO and CBO+1 (732)
